Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

870.49 +20.50 (+2.41%)
Streaming Delayed Price Updated: 3:26 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
81 82 Next >
Harvard Business Professor on Failing Well
Why would Eli Lilly put on a failure party? 
Via The Motley Fool
Assessing Eli Lilly and Co's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
What the Options Market Tells Us About Eli Lilly and Co
Via Benzinga
Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts
Goldman Sachs predicts a potential 1% GDP boost from GLP-1 agonists market. Novo Nordisk and Eli Lilly lead, with analysts foreseeing 10-70 million users by 2028. AI-powered drug discovery and... 
Via Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
Could Eli Lilly Stock Help You Become a Millionaire?
Shares of Eli Lilly have risen by roughly 1,190% over the past 10 years. 
Via The Motley Fool
Eli Lilly Unusual Options Activity
Via Benzinga
Where Will Eli Lilly Be in 5 Years?
The stock will still be crushing the market in all likelihood. 
Via The Motley Fool
Here's 1 Pharmaceutical Stock That Looks Unstoppable. Hint: It's Not Novo Nordisk.
Eli Lilly is home to many blockbuster drugs including Mounjaro, Jardiance, Zepbound, and more. 
Via The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Why Eli Lilly Stock Was Feeling Sickly on Wednesday
The company's surging popularity has made it expensive in terms of valuation. 
Via The Motley Fool
Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for February 2024
Here are just a few of the top growth stocks investors may want to seriously consider as we get deeper into the new year. 
Via InvestorPlace
3 Stocks With the Potential to Knock Tesla Out of the Magnificent 7
These stocks are best positioned to usurp Tesla's position within Magnificent 7 stocks as it slumps further in February. 
Via InvestorPlace
Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly Has More Than an Ozempic Competitor -- Much More
Eli Lilly's hottest treatment might be Mounjaro, but the company has a lot more at its disposal. 
Via The Motley Fool
Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade
In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. 
Via Investor's Business Daily
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
Predicting top sectors isn't easy; we usually identify them only in hindsight, but these three stock market segments are rapidly rising. 
Via InvestorPlace
3 Cheap Dividend Stocks to Snatch Up Now
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors. 
Via InvestorPlace
Top 7 Contenders to Join the Trillion-Dollar Club
Microsoft's ascent to the $3 trillion mark highlights the growing influence of trillion-dollar companies in the stock market. 
Via InvestorPlace
Eli Lilly & Company Should Continue Bullish Rally
Eli Lilly & Company discovers, develops & markets human pharmaceuticals worldwide. It is having around 742 B$ market cap as of 16 February 2024. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Magnificent Growth Stocks to Buy Right Now
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects. 
Via The Motley Fool
3 Stocks Primed to Reach Trillion-Dollar Valuation
Explore the elite world of trillion-dollar stocks and uncover insights on the companies dominating the market with unparalleled valuations. 
Via InvestorPlace
Warren Buffett's Empire Nears Trillion-dollar Club As Class A Shares Hit Above $600,000
This week, Berkshire Hathaway (NYSE: BRK-A) achieved a historic milestone as its Class A shares closed above $600,000 for the first time. 
Via Benzinga
Four Charts Every Trader Needs To See Today
As I’ve noted previously, the S&P 500 is quite extended above both its 10-week moving average (same as the 50-DMA) as well as the 40-week moving average (same as the 200-DMA). 
Via Talk Markets
Topics Stocks
Exposures US Equities
SPDR ETF Report For Friday, February 16
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Friday, February 16. 
Via Talk Markets
Topics ETFs
Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?
Eli Lilly's weight-loss and diabetes treatments Zepbound and Mounjaro should drive LLY stock much higher, said a Morgan Stanley analyst. 
Via Investor's Business Daily
My Top 3 Stock Candidates to Replace Tesla in the Magnificent 7
The Magnificent 7 stocks are mostly doing well in 2024. It would still be a good bet if not for Elon Musk’s company. 
Via InvestorPlace
What The Future Holds For Google's 'Other Bets'
Alphabet's far-ranging Other Bets tickle imaginations, but they've piled up huge losses. Google stock could benefit as discipline is imposed. 
Via Investor's Business Daily
Ray Dalio's Bridgewater Makes Waves: Q4 Unveils Strategic Shifts With New Investments, Sector Expansion In Tech
Bridgewater Associates, founded by Ray Dalio, made notable changes to its portfolio in Q4 2023. New bets, exits, increased stakes offer insights into its investment strategy. 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
81 82 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.